Skip to content

Prospective observational study on pain relief, functional evaluation and safety of Ainprose for acute and chronic pain Singl-center, single-arm open study

Prospective observational study on pain relief, functional evaluation and safety of Ainprose for acute and chronic pain Singl-center, single-arm open study - Observational Study of Ainprose for Pain

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000049726
Enrollment
30
Registered
2022-12-08
Start date
2025-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pain and Chronic pain

Interventions

None listed

Sponsors

General incorporated association Advalife Science SINCLAIR GINZA CLINIC
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Men and women between the ages of 20 and 80 years old. 2.Patients with pain symptoms in the following areas Neck. Shoulder joint. Knee joint Lower back. Ankle joint (including foot) 3.Patients who have given written consent to participate in the study

Exclusion criteria

Exclusion criteria: 1. Patients who have taken anti-inflammatory analgesics within 8 hours prior to the administration of the study drug 2. Patients who have used sleeping pills, psychotropic drugs, or other psychiatric drugs within 24 hours prior to administration of the study drug 3. Patients suffering from infectious diseases 4. Patients with a history of cancer or active malignancy 5. Patients with hypoglycemic symptoms prior to administration of the study drug 6. Patients who are judged to be inappropriate as research subjects by the principal investigator and principal study investigator

Design outcomes

Primary

MeasureTime frame
Perform pain and functional assessment prior to administration of the study drug, pain and functional assessment 30 minutes after administration, pain and functional assessment 24 hours after administration, pain and functional assessment 7days after administration,pain and functional assessment 14 days after administration

Countries

Japan

Contacts

Public ContactAyumi Masuyama

General incorporated association Advalife Science SINCLAIR GINZA CLINIC Nursing Deptment

masuyama@s-gc.jp03-3538-6082

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026